Post hoc analyses for the LTE period
The primary endpoint for the LTE period in this study was the incidence of AEs and SAEs over the placebo-controlled and LTE periods. Analyses of key exploratory endpoints included continued assessment of the efficacy endpoints from the placebo-controlled period, such as CDR-SB, ADAS-Cog13, MMSE, ADCS-ADL and FAQ scores.